
Upcoming Stock Splits This Week (June 30 to July 4)
These are the upcoming stock splits for the week of June 30 to July 4, based on TipRanks' Stock Splits Calendar. In simple terms, a stock split boosts the number of outstanding shares by issuing more to current shareholders, while keeping the company's overall market value intact. This maneuver lowers the share price, often making the stock more affordable, and therefore more appealing, to everyday investors.
Don't Miss TipRanks' Half Year Sale
Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
On the flip side, some companies choose a reverse stock split, merging shares rather than dividing them. This trims the total share count while raising the price per share, again without changing the company's total market worth. Reverse splits are frequently used to meet minimum price requirements on exchanges like the Nasdaq and help avoid delisting.
Whether aiming to attract more investors or stay in good standing with exchanges, these corporate moves can send important signals that investors watch closely.
Let's take a look at the upcoming stock splits for the week.
Ainos (AIMD) – Ainos is a dual-platform AI and biotech company, developing the 'AI Nose' scent digitization platform alongside oral interferon therapeutics for rare and autoimmune diseases. On June 26, Ainos announced a 1‑for‑5 reverse stock split, aiming to lift its share price above Nasdaq's minimum. The split will take effect at market open on June 30.
Helius Medical Technologies (HSDT) – Helius Medical Technologies, known for its innovative neuromodulation devices like the PoNS® platform for neurological recovery, announced a 1-for-50 reverse stock split on June 27 to maintain compliance with Nasdaq listing requirements. The split will take effect on June 30, with Helius shares set to trade on a split-adjusted basis starting July 1.
APi Group (APG) – APi Group specializes in safety, specialty, and industrial services. On May 21, APG announced a 3‑for‑2 forward stock split, conceived to lower per‑share price, increase retail access, and improve liquidity. The ex‑date is July 1, with adjusted trading beginning that day.
Channel Therapeutics (CHRO) – Channel Therapeutics is a pain‑treatment biotech preparing for a merger with Pelthos Therapeutics and a NYSE American uplist. On June 27, the company announced a 10‑for‑1 reverse split to comply with listing standards and support a $50 million private placement. The split is effective before market open July 1, with split‑adjusted trading under 'Pelthos Therapeutics' starting July 2.
SciSparc (SPRC) – Tel Aviv–based SciSparc, a clinical-stage developer of central nervous system therapies, announced on June 24 a 1-for-21 reverse share split to raise its share price and maintain compliance with Nasdaq listing standards. The split will take effect at market open on July 3.
TipRanks Stock Splits Calendar.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
FORT MYERS, Fla., July 01, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 859170. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. View source version on Contacts Investor Contact Kendra Websterir@ Media Contact Andrea Sampsonasampson@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Insider
18 minutes ago
- Business Insider
UBS Reaffirms Their Buy Rating on Symrise (0G6T)
In a report released today, Charles Eden from UBS maintained a Buy rating on Symrise (0G6T – Research Report), with a price target of €115.00. The company's shares closed yesterday at €89.14. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Eden covers the Consumer Defensive sector, focusing on stocks such as Givaudan SA, Symrise, and Kerry Group plc. According to TipRanks, Eden has an average return of -0.4% and a 48.06% success rate on recommended stocks. Currently, the analyst consensus on Symrise is a Moderate Buy with an average price target of €114.91, implying a 28.91% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a €120.00 price target.


Business Wire
23 minutes ago
- Business Wire
(Agency for Medicinal Products and Medical Devices of the Republic of Slovenia)
BORDEAUX, France & LJUBLJANA, Slovenia--(BUSINESS WIRE)--FineHeart S.A., a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announces that it has received authorization from JAZMP, the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia, to begin its First-In-Human (FIH) clinical study. This prospective, non-randomized study is designed to assess the safety, implant feasibility and preliminary clinical performance of the FlowMaker® device in patients with advanced heart failure. FlowMaker® is a new-generation, fully implantable left ventricular assist device designed to work in synergy with the heart's natural contraction. Less invasive than current devices, this technology aims to preserve native cardiac function while significantly improving patients' quality of life. Professor Ivan Kneževič, cardio surgeon and director of the Transplantation Centre of the University Medical Centre in Ljubljana, will lead the study. " It is a real privilege to take part in this first FIH study. FlowMaker represents a major technological advance in the treatment of patients with advanced heart failure" he said. Arnaud Mascarell, CEO and co-founder of FineHeart, comments: " Following approvals in the Czech Republic and France, the Slovenian authorization represents another strong endorsement of our preliminary clinical results and our technology by European health authorities. It reflects the growing confidence within the cardiology community in our disruptive approach. This latest green light reinforces our clinical strategy across Europe—a critical step toward securing CE marking. Our goal remains clear: to deliver an innovative, less invasive solution for patients with advanced heart failure, where current treatment options remain limited." About FineHeart - FineHeart